Esperion Therapeutis.Inc. buy Maxi_Scalibusa
Summary
This prediction ended on 22.05.18 with a price of €34.91. The BUY prediction by Maxi_Scalibusa for Esperion Therapeutis.Inc. performed very badly with a performance of -49.25%. Maxi_Scalibusa has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | 5.214% | 5.214% | 43.118% | -89.307% |
iShares Core DAX® | 4.094% | 4.888% | 17.421% | 22.413% |
iShares Nasdaq 100 | 1.424% | -0.445% | 37.618% | 58.203% |
iShares Nikkei 225® | -1.572% | -4.911% | 12.951% | 7.961% |
iShares S&P 500 | 1.822% | 0.776% | 29.182% | 49.914% |
Comments by Maxi_Scalibusa for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Hot Stock